Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care reports first quarter results in line with its expectations despite significant headwinds: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care reports first quarter results in line with its expectations despite significant headwinds
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care reports first quarter results in line with its expectations despite significant headwinds
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet to succeed Rice Powell as Chief Executive Officer of Fresenius Medical Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet to succeed Rice Powell as Chief Executive Officer of Fresenius Medical Care
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet to succeed Rice Powell as Chief Executive Officer of Fresenius Medical Care
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10http://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approvedhttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approved
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approved
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest
DGAP-News: Carl Zeiss Meditec acquires two manufacturers of surgical instrumentshttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-News: Carl Zeiss Meditec acquires two manufacturers of surgical instruments
DGAP-News: Carl Zeiss Meditec acquires two manufacturers of surgical instruments
STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.
STAAR Surgical Announces First Implants of EVO Visian ICL in the U.S.


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the EVO

Waters stellt Xevo TQ Absolute vor – das empfindlichste und kompakteste Tandem-Quadrupol-Massenspektrometer für den Tischeinsatz
Waters stellt Xevo TQ Absolute vor – das empfindlichste und kompakteste Tandem-Quadrupol-Massenspektrometer für den Tischeinsatz


Waters Corporation (NYSE:WAT) hat heute das neue System Xevo™ TQ Absolute vorgestellt, das empfindlichste und kompakteste Tandem-Massenspektrometer seiner Klasse für den Tischeinsatz.i


Diese

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will

Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005765/en/



Dr. Alessandro Riva (Photo: Transgene)




Transgene

Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer
Waters Introduces Xevo TQ Absolute – The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer


Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i


This press release features multimedia

STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that the U.S. Food and Drug

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results


This press release is being re-issued to revise the language in the Selling, General and Administrative bullet under Financial Results. That third bullet, third sentence should read: The net

Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen
Waters präsentiert eine schnellere, zuverlässigere und automatisierte Lösung für die Massen- und Reinheitsanalyse von Biomolekülen


Die Waters Corporation (NYSE:WAT) stellte heute neue Software und analytische Säulen zur Unterstützung der Erforschung und Entwicklung von Biomolekülen vor. Mit der neuen App 'Intact Mass' von

Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules
Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules


Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows

Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren
Dexcom G7 erhält CE-Kennzeichnung – Das kontinuierliche Blutzuckermesssystem der nächsten Generation wird das Diabetesmanagement revolutionieren


DexCom, Inc. (NASDAQ:DXCM), der weltweit führende Anbieter im Bereich der kontinuierlichen Blutzuckermessung in Echtzeit für Menschen mit Diabetes, gab heute bekannt, dass das Unternehmen die

Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7

Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®


Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral

Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program
Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program


Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage

Humana Launches CenterWell Home Health
Humana Launches CenterWell Home Health


One year after launching the CenterWell brand to represent Humana’s payer-agnostic healthcare service offerings, Humana Inc. (NYSE: HUM) has started to transition Kindred at Home’s home health